Interaction of thiazolidinediones (glitazones) with the ATP-Binding cassette transporters P-glycoprotein and breast cancer resistance protein

Pharmacology

Volumn 84, Issue 5, 2009, Pages 264-270

  Weiss, Johanna ^a   Sauer, Alexandra ^a   Herzog, Melanie ^a   Böger, Rainer H ^b   Haefeli, Walter E ^a   Benndorf, Ralf A ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Breast cancer resistance protein; Glitazone; P glycoprotein; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABC TRANSPORTER; ANTIDIABETIC AGENT; BREAST CANCER RESISTANCE PROTEIN; COMPLEMENTARY DNA; FUMITREMORGIN C; GLITAZONE DERIVATIVE; GLYCOPROTEIN P; LACTATE DEHYDROGENASE; MESSENGER RNA; PIOGLITAZONE; RIFAMPICIN; ROSIGLITAZONE; TROGLITAZONE; VERLUKAST; ZOSUQUIDAR;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DIABETES MELLITUS; DRUG EFFECT; DRUG PROTEIN BINDING; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; FLUOROMETRY; HUMANS; HYPOGLYCEMIC AGENTS; MICE; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIAZOLIDINEDIONES;

EID: 70349264523     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000241734     Document Type: Article

References (48)

1. Szaka ́cs G, Váradi A, Ozvegy-Laczka C, Sarkadi B: The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 2008; 13: 379-393.
2. Schinkel AH, Smit JJ, Van Tellingen O, Beijnen JH, Wagenaar E, Van Deemter L, Mol CA, Van Der Valk MA, Robanus-Maandag EC, te Riele HP, et al: Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491-502.
3. Cordon -Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR: Multidrug-resistance gene (Pglycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989; 86: 695-698.
4. Van Asperen J, Van Tellingen O, Beijnen JH: The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol Res 1998; 37:429-435.
5. Kusuhara H, Suzuki H, Sugiyama Y: The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. J Pharm Sci 1998; 87: 1025-1040.
6. Chiou WL, Chung SM, Wu TC: Potential role of P-glycoprotein in affecting hepatic metabolism of drugs. Pharm Res 2000; 17: 903-905.
7. Yu DK: The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 1999; 39: 1203-1211.
8. Mao Q, Unadkat JD: Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 2005; 7:E118-E133.
9. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, Beijnen JH, Schinkel AH: The breast cancer resistance protein protects against a major chlorophyllderived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 2002; 99: 15649-15654.
10. Van Herwaarden AE, Schinkel AH: The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. Trends Pharmacol Sci 2006; 27: 10-16.
11. Van Herwaarden AE, Wagenaar E, Karnekamp B, Merino G, Jonker JW, Schinkel AH: Breast cancer resistance protein (Bcrp1/ Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp- P-1 but also mediates their secretion into breast milk. Carcinogenesis 2006; 27: 123-130.
12. Breedveld P, Zelcer N, Pluim D, Sönmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JH: Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 2004; 64: 5804-5811.
13. Cho N, Momose Y: Peroxisome proliferatoractivated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress. Curr Top Med Chem 2008; 8: 1483-1507.
14. Yki-Järvinen H: Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
15. Henney JE: From the Food and Drug Administration. JAMA 2000; 283: 2228.
16. Solbach TF, Paulus B, Weyand M, Eschenhagen T, Zolk O, Fromm MF: ATP-binding cassette transporters in human heart failure. Naunyn Schmiedebergs Arch Pharmacol 2008; 377: 231-243.
17. Enokizono J, Kusuhara H, Sugiyama Y: Involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect. Drug Metab Dispos 2007; 35: 209-214.
18. Szatmari I, Vamosi G, Brazda P, Balint BL, Benko S, Széles L, Jeney V, Ozvegy-Laczka C, Szántó A, Barta E, Balla J, Sarkadi B, Nagy L: Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells. J Biol Chem 2006; 281: 23812-23823.
19. Boesch D, Gavériaux C, Jachez B, Pourtier- Manzanedo A, Bollinger P, Loor F: In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 1991; 51: 4226-4233.
20. Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J: Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 2007; 73: 1573-1581. (Pubitemid 46527547)
21. Pavek P, Merino G, Wagenaar E, Bolscher E, Novotna M, Jonker JW, Schinkel AH: Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6- phenylimidazo(4,5- b )pyridine, and transport of cimetidine. J Pharmacol Exp Ther 2005; 312: 144-152.
22. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J: Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982; 42: 3858-3863.
23. Fröhlich M, Albermann N, Sauer A, Walter- Sack I, Haefeli WE, Weiss J: In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. Biochem Pharmacol 2004; 68: 2409-2416.
24. Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, Haefeli WE, Efferth T: Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 2007; 59: 238-245.
25. Storch CH, Ehehalt R, Haefeli WE, Weiss J: Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J Pharmacol Exp Ther 2007; 323: 257-264.
26. Peters T, Lindenmaier H, Haefeli WE, Weiss J: Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2006; 372: 291-299.
27. Weiss J, Herzog M, König S, Storch CH, Ketabi- Kiyanvash N, Haefeli WE: Induction of multiple drug transporters by efavirenz. J Pharmacol Sci 2009; 109: 242-250.
28. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: 1-11.
29. Albermann N, Schmitz-Winnenthal FH, Z'graggen K, Volk C, Hoffmann MM, Haefeli WE, Weiss J: Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 2005; 70: 949-958.
30. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003; 305: 197-204.
31. Weiss J, Haefeli WE: Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: F 2 values. Drug Metab Dispos 2006; 34: 203-207.
32. Peters AL: Using thiazolidinediones: rosiglitazone and pioglitazone in clinical practice. Am J Manag Care 2001; 7:S87-S95.
33. Kalaitzidis RG, Sarafidis PA, Bakris GL: Effects of thiazolidinediones beyond glycaemic control. Curr Pharm Des 2009; 15: 529-536.
34. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471. (Pubitemid 46919772)
35. Singh S, Loke YK, Furberg CD: Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298: 1189-1195.
36. Erdmann E, Wilcox RG: Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur Heart J 2008; 29: 12-20.
37. Scheen AJ: Pharmacokinetic interactions with thiazolidinediones. Clin Pharmacokinet 2007; 46: 1-12.
38. Jones SA, Moore LB, Shenk JL, Wisely GB, Hamilton GA, McKee DD, Tomkinson NC, LeCluyse EL, Lambert MH, Willson TM, Kliewer SA, Moore JT: The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 2000; 14: 27-39.
39. Ramachandran V, Kostrubsky VE, Komoroski BJ, Zhang S, Dorko K, Esplen JE, Strom SC, Venkataramanan R: Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes. Drug Metab Dispos 1999; 27: 1194-1199.
40. Sahi J, Black CB, Hamilton GA, Zheng X, Jolley S, Rose KA, Gilbert D, LeCluyse EL, Sinz MW: Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos 2003; 31: 439-446.
41. Ebert B, Seidel A, Lampen A: Identification of BCRP as transporter of benzo[ a ]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis 2005; 26: 1754-1763.
42. Zhang Y, Zhou G, Wang H, Zhang X, Wei F, Cai Y, Yin D: Transcriptional upregulation of breast cancer resistance protein by 17betaestradiol in ERalpha-positive MCF-7 breast cancer cells. Oncology 2006; 71: 446-455.
43. Plosker GL, Faulds D: Troglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 1999; 57: 409-438.
44. Gillies PS, Dunn C: Pioglitazone. Drugs 2000; 60: 333-343.
45. Deeks ED, Keam SJ: Rosiglitazone: a review of its use in type 2 diabetes mellitus. Drugs 2007; 67: 2747-2779.
46. Loi CM, Knowlton PW, Stern R, Randinitis EJ, Vassos AB, Koup JR, Sedman AJ: Effect of troglitazone on steady-state pharmacokinetics of digoxin. J Clin Pharmacol 1998; 38: 178-183.
47. Di Cicco RA, Miller AK, Patterson S, Freed MI: Rosiglitazone does not affect the steadystate pharmacokinetics of digoxin. J Clin Pharmacol 2000; 40: 1516-1521.
48. Park JY, Kim KA, Kang MH, Kim SL, Shin JG: Effect of rifampicin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther 2004; 75: 157-162.